Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 1525 of 3284 entries
View as:

AZD6244 vs. Capecitabine (Xeloda®) in Patients With Advanced or Metastatic Pancreatic Cancer, Who Have Failed First Line Gemcitabine Therapy

Phase: N/A Priority: Normal
NCT ID: NCT00372944 Org: User:
Start: 08/31/06 End: 10/31/08 Due: 10/31/09

Bioequivalence Study of the Fixed Dose Combination of 5 mg Saxagliptin and 500 mg Metformin XR Tablet (Manufactured in Mt Vernon, IN) Relative to 5 mg Saxagliptin Tablet and 500 mg Metformin XR Tablet (Manufactured in Evansville, IN)

Phase: N/A Priority: Normal
NCT ID: NCT01192139 Org: User:
Start: 11/30/09 End: 12/31/09 Due: 12/31/10

Evaluate Efficacy and Safety of Saxagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes

Phase: N/A Priority: Normal
NCT ID: NCT00661362 Org: User:
Start: 06/30/08 End: 09/30/09 Due: 09/30/10

A Phase 3 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults and Adolescents With Uncontrolled Asthma

Phase: N/A Priority: Normal
NCT ID: NCT02194699 Org: User:
Start: 10/30/14 End: 09/21/17 Due: 09/21/18

Study to Investigate Relative Bioavailability of up to Five Different Formulations of AZD5069

Phase: N/A Priority: Normal
NCT ID: NCT01989520 Org: User:
Start: 01/31/14 End: 04/30/14 Due: 04/30/15

A Study in Participants With Non-cirrhotic NASH With Fibrosis

Phase: N/A Priority: Normal
NCT ID: NCT05638737 Org: User:
Start: 10/26/22 End: 04/04/24 Due: 04/04/25

Long Term Open Follow-up With H376/95 vs. Warfarin

Phase: N/A Priority: Normal
NCT ID: NCT00206063 Org: User:
Start: 08/31/99 End: 04/30/06 Due: 04/30/07

Study to Investigate the Effects of AZD6140 in Patients With Renal Impairment and in Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT00733265 Org: User:
Start: 02/28/07 End: 09/30/08 Due: 09/30/09

Bleeding Time Study With AZD6482, Clopidogrel and ASA

Phase: N/A Priority: Normal
NCT ID: NCT00853450 Org: User:
Start: 02/28/09 End: 07/31/09 Due: 07/31/10

14729-D9831C00002- 1 Month Biopsy Study

Phase: N/A Priority: Normal
NCT ID: NCT00766415 Org: User:
Start: 11/30/08 End: 06/30/09 Due: 06/30/10

Efficacy and Safety of Quetiapine Fumarate (SEROQUEL®) in the Treatment of Alcohol Dependency in Patients With Bipolar Disorder

Phase: N/A Priority: Normal
NCT ID: NCT00114686 Org: User:
Start: 01/31/06 End: 04/30/07 Due: 04/30/08

Tagrisso Tablets Clinical Experience Investigation (All Case Investigation)

Phase: N/A Priority: Normal
NCT ID: NCT02756039 Org: User:
Start: 05/25/16 End: 08/31/18 Due: 08/31/19

Determine the Effects of C-administration of AZD7325 and an Oral Contraceptive in Healthy Female Subjects

Phase: N/A Priority: Normal
NCT ID: NCT00901290 Org: User:
Start: 05/31/09 End: 09/30/09 Due: 09/30/10

Study Assessing Saxagliptin Treatment In Type 2 Diabetic Subjects Who Are Not Controlled With Metformin Alone

Phase: N/A Priority: Normal
NCT ID: NCT00121667 Org: User:
Start: 08/31/05 End: 02/28/10 Due: 02/28/11

Phase Ib Study to Determine MTD of AZD1775 Monotherapy in Patients With Locally Advanced or Metastatic Solid Tumours.

Phase: N/A Priority: Normal
NCT ID: NCT02610075 Org: User:
Start: 12/01/15 End: 04/26/18 Due: 04/26/19

Uric Acid Study in Healthy Male Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT00738842 Org: User:
Start: 05/31/08 End: 07/31/08 Due: 07/31/09

Exenatide Versus Glimepiride in Patients With Type 2 Diabetes

Phase: N/A Priority: Normal
NCT ID: NCT00359762 Org: User:
Start: 09/30/06 End: 03/31/11 Due: 03/31/12

A Study to Assess the Pharmacokinetics and Safety of Budesonide, Glycopyrronium, & Formoterol (BGF) Metered Dose Inhaler (MDI) Hydrofluoroolefin (HFO) With a Spacer (Treatment B), BGF MDI Hydrofluoroalkane (HFA) With a Spacer (Treatment A), as Well as BGF MDI HFO Without a Spacer (Treatment C).

Phase: N/A Priority: Normal
NCT ID: NCT06297668 Org: User:
Start: 04/29/24 End: 06/11/24 Due: 06/11/25

Phase I Study to Evaluate Bioavailability of Naproxen as PN400 Compared to Naproxen as Naprosyn E

Phase: N/A Priority: Normal
NCT ID: NCT00907400 Org: User:
Start: 05/31/09 End: 09/30/09 Due: 09/30/10

Multiple Ascending Doses of AMG 139 in Healthy and Crohn's Disease Subjects

Phase: N/A Priority: Normal
NCT ID: NCT01258205 Org: User:
Start: 02/28/11 End: 02/18/15 Due: 02/18/16

A Study to Investigate the Potential for AZD5672 to Affect the Electrical Conduction Pathways in the Heart

Phase: N/A Priority: Normal
NCT ID: NCT00887770 Org: User:
Start: 04/30/09 End: 07/31/09 Due: 07/31/10

A Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour Resection

Phase: N/A Priority: Normal
NCT ID: NCT05120349 Org: User:
Start: 02/21/22 End: 11/01/32 Due: 11/01/33

Study to Investigate Single Ascending Oral Doses of AZD5213 in Healthy Male and Non Fertile Female Subjects

Phase: N/A Priority: Normal
NCT ID: NCT01121302 Org: User:
Start: 05/31/10 End: 12/31/10 Due: 12/31/11

Positron Emission Tomography (PET) Study

Phase: N/A Priority: Normal
NCT ID: NCT00886067 Org: User:
Start: 04/30/09 End: 08/31/09 Due: 08/31/10

AZD4076 in Type 2 Diabetic Subjects With Non-Alcoholic Fatty Liver Disease.

Phase: N/A Priority: Normal
NCT ID: NCT02826525 Org: User:
Start: 07/18/16 End: 10/11/19 Due: 10/11/20